No, CTCs Are a Component of Liquid Biopsy, Not Synonymous With It
Circulating tumor cells (CTCs) represent one specific type of liquid biopsy biomarker, but the term "liquid biopsy" encompasses a broader category of cancer-related analytes obtained from blood and other body fluids. 1
Understanding the Distinction
What Liquid Biopsy Actually Includes
The "tumor circulome" comprises multiple distinct biomarkers 1:
- Circulating tumor cells (CTCs) - intact living tumor cells
- Extracellular vesicles (EVs) - including exosomes and microvesicles
- Cell-free tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
- Circulating tumor RNA (ctRNA)
- Tumor-educated platelets (TEPs)
All of these qualify as liquid biopsies because they are obtained through minimally invasive blood draws rather than tissue biopsies 1.
Key Biological Differences
CTCs are fundamentally different from other liquid biopsy components because they are living, intact tumor cells that can be recovered and potentially cultured 1. In contrast, EVs represent "dead material with transient effects on recipient cells" 1. This distinction has major implications:
- CTCs can be cultured in vitro and used to create CTC-derived xenograft (CDX) models for studying tumor biology 2
- CTCs maintain cellular architecture allowing for comprehensive molecular profiling of the genome, transcriptome, proteins, and epigenome 3
- CTCs are extremely rare - typically only a few cells among billions of erythrocytes and leukocytes 4
Clinical Context
FDA Approval Status
CTC detection methodology is partially FDA-approved and in clinical use 1, with the CellSearch® system representing the clinical gold standard primarily for metastatic disease 5. However, this represents only one component of the broader liquid biopsy landscape.
Practical Implications
When ordering or interpreting tests:
- A "CTC assay" specifically enumerates circulating tumor cells 6, 7
- A "liquid biopsy" could refer to CTC analysis, ctDNA testing, exosome profiling, or combinations thereof
- The clinically relevant CTC threshold is ≥5 CTCs per 7.5 mL of blood for prognostic stratification 6
Common Pitfall to Avoid
Do not use "liquid biopsy" and "CTC" interchangeably in clinical documentation or when ordering tests. Specify which liquid biopsy component you are analyzing, as each provides different information and has distinct clinical utilities. CTCs excel at providing information about viable tumor cells and metastatic potential 2, 3, while ctDNA may be superior for detecting specific mutations, and EVs offer insights into tumor-microenvironment interactions 1.
The terminology matters because different liquid biopsy modalities require different collection protocols, processing methods, and interpretation frameworks 5.